- Home
- SOR vs LXRX Comparison
SOR vs LXRX Comparison
Compare SOR & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- LXRX
- Stock Information
- Founded
- SOR 1968
- LXRX 1995
- Country
- SOR United States
- LXRX United States
- Employees
- SOR N/A
- LXRX N/A
- Industry
- SOR Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- LXRX Health Care
- Exchange
- SOR Nasdaq
- LXRX Nasdaq
- Market Cap
- SOR 358.4M
- LXRX 392.2M
- IPO Year
- SOR N/A
- LXRX 2000
- Fundamental
- Price
- SOR $43.55
- LXRX $1.07
- Analyst Decision
- SOR
- LXRX Buy
- Analyst Count
- SOR 0
- LXRX 4
- Target Price
- SOR N/A
- LXRX $3.67
- AVG Volume (30 Days)
- SOR 16.2K
- LXRX 3.5M
- Earning Date
- SOR 01-01-0001
- LXRX 08-06-2025
- Dividend Yield
- SOR 7.24%
- LXRX N/A
- EPS Growth
- SOR N/A
- LXRX N/A
- EPS
- SOR 6.50
- LXRX N/A
- Revenue
- SOR N/A
- LXRX $31,213,000.00
- Revenue This Year
- SOR N/A
- LXRX N/A
- Revenue Next Year
- SOR N/A
- LXRX N/A
- P/E Ratio
- SOR $6.41
- LXRX N/A
- Revenue Growth
- SOR N/A
- LXRX 1251.21
- 52 Week Low
- SOR $36.41
- LXRX $0.28
- 52 Week High
- SOR $42.75
- LXRX $2.25
- Technical
- Relative Strength Index (RSI)
- SOR 50.86
- LXRX 52.30
- Support Level
- SOR $43.31
- LXRX $1.00
- Resistance Level
- SOR $44.58
- LXRX $1.11
- Average True Range (ATR)
- SOR 0.98
- LXRX 0.10
- MACD
- SOR -0.07
- LXRX -0.03
- Stochastic Oscillator
- SOR 50.48
- LXRX 16.28
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.